Gómez-Pérez, Ana MaríaGarcía-Alemán, JorgeMolina-Vega, MaríaSebastián Ochoa, ArantzazuPérez García, PilarMancha Doblas, IsabelTinahones, Francisco J2025-01-072025-01-072020-02-212077-0383https://hdl.handle.net/10668/27071(1) Background-low-dose radioiodine ablation is an accepted strategy for the treatment of low- and intermediate-risk thyroid carcinomas, although there is no international consensus. The aim of this study is to describe the clinical experience with low-dose radioiodine ablation in patients with low- and intermediate-risk thyroid cancer compared to high-dose ablation. (2) Methods-174 patients with low- and intermediate-risk thyroid cancer, 90 treated with low-dose ablation and 84 treated with high-dose ablation, were included. The primary endpoint was response to treatment one year after ablation, defined by stimulated thyroglobulin, whole body scan and ultrasound imaging. (3) Results-an excellent response rate of 79.8% in the low-dose group and 85.7% in the high-dose group was observed (p = 0.049). Stimulated thyroglobulin at the moment of ablation (p = 0.032) and positive antithyroglobulin antibodies (penAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/antithyroglobulin antibodiesdifferentiated thyroid cancerlow-dose ablationlow-riskradioiodineresearch article32098039open access10.3390/jcm9020581PMC7074446https://www.mdpi.com/2077-0383/9/2/581/pdf?version=1582278271https://pmc.ncbi.nlm.nih.gov/articles/PMC7074446/pdf